HC Wainwright & Co. Reiterates Axsome Therapeutics (AXSM) Buy Recommendation
18/4 04:20
Fintel reports that on April 17, 2023, HC Wainwright & Co. reiterated coverage of Axsome Therapeutics (NASDAQ:AXSM) with a Buy recommendation. Analyst Price Forecast Suggests 54.98% Upside...